Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter

Tundra lists 1 Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT04724018

Sacituzumab Govitecan Plus EV in Metastatic UC

Phase I of this research study will assess what doses of Sacituzumab Govitecan and Enfortumab Vedotin can be safely combined in the treatment of metastatic urothelial carcinoma (mUC). In Phase II of the study, patients in one of the two cohorts will receive Sacituzumab Govitecan, Enfortumab Vedotin, and Pembrolizumab to assess the efficacy of this drug combination. The names of the study drugs in these investigational combinations are: * Enfortumab Vedotin * Sacituzumab Govitecan * Pembrolizumab

Gender: All

Ages: 18 Years - Any

Updated: 2025-11-04

1 state

Urothelial Cancer

Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter